World Health Organization to Review Cannabis

It is going largely unknown, unreported and ignored that the World Health Organization (WHO) the arm of the UN that controls the schedule of substances is looking at Cannabis.

As part of the UN the US and the FDA is looking for input from people and organizations about the changes and surprisingly no one is commenting.  The comment period ends Feb 10th at midnight eastern time and so far they have gotten 3 comments.

https://www.regulations.gov/docket?D=FDA-2016-N-4619

3 comments, that is really pretty sad considering a change in the scheduling of Cannabis on an international level could lead to changes in scheduling on a federal level here in the US.

The United States is also a party to the 1961 Single Convention on Narcotic Drugs (1961 Single Convention). The Secretary of State has received a notification from the Secretary-General regarding two substances to be considered for control under this convention. The CSA does not require HHS to publish a summary of such information in the Federal Register. Nevertheless, in an effort to provide interested and affected persons an opportunity to submit comments regarding the WHO recommendations for narcotic drugs, the notification regarding these substances is also included in this Federal Register notice. The comments will be shared with other relevant Agencies to assist the Secretary of State in formulating the position of the United States on the control of these substances. The HHS recommendations are not binding on the representative of the United States in discussions and negotiations relating to the proposal regarding control of substances under the 1961 Single Convention.

Of the substances being considered

The Committee recommended that a specific ECDD meeting dedicated to cannabis and its component substances should be held within the next eighteen months from the 38th meeting, and will carry out pre-reviews for the following substances:

—Cannabis plant and cannabis resin;

—Extracts and tinctures of cannabis;

—Delta-9-tetrahydrocannabinol (THC);

—Cannabidiol (CBD);

—Stereoisomers of THC.

The recommendations and the assessments and findings on which they are based are set out in detail in the Report of the 38th Expert Committee on Drug Dependence, which is the Committee that advises me on these issues. An extract of the Committee’s Report is attached in Annex 1 to this letter.

 

Here is a copy of the WHO Review Report – WHO-cannabis-report